DEXA Body Composition: Which Tests to Order Alongside

What a DEXA Body Composition Scan Actually Measures

DEXA (dual-energy X-ray absorptiometry) passes two low-dose X-ray beams through tissue at different energy levels. The attenuation difference lets the software partition every region of your body into three compartments: fat mass, lean soft tissue (muscle, organs, water), and bone mineral content [1]. The result is a three-compartment model that is more precise than bioelectrical impedance or skinfold calipers.

A 2019 systematic review in the British Journal of Sports Medicine (N=3,228 across 30 studies) reported DEXA whole-body fat mass has a test-retest coefficient of variation between 1.0% and 2.5%, making it the clinical reference standard for longitudinal body composition tracking [2]. That precision matters when you are monitoring lean mass preservation on a GLP-1 receptor agonist or testosterone replacement therapy.

What the scan does not tell you is equally important. DEXA cannot distinguish visceral from subcutaneous fat with the accuracy of CT or MRI (though newer CoreScan algorithms estimate visceral adipose tissue in the android region). It cannot explain whether low lean mass reflects hormonal deficiency, protein malnutrition, chronic inflammation, or simple disuse. The scan gives you the "what." Blood work provides the "why."

The Core Metabolic Panel Every DEXA Patient Needs

Order these alongside every DEXA scan, regardless of the clinical question: a comprehensive metabolic panel (CMP), fasting insulin, HbA1c, and a standard lipid panel. These four tests cost under $50 at most direct-pay labs and form the metabolic backbone for interpreting body composition data.

Fasting insulin deserves special attention. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that "insulin resistance is the single strongest metabolic correlate of excess adiposity and should be assessed when body composition is measured" [3]. A fasting insulin above 15 µIU/mL alongside a DEXA-derived fat mass index (FMI) above 9 kg/m² in men or 13 kg/m² in women signals a metabolic phenotype that responds differently to GLP-1 therapy than insulin-sensitive obesity does.

HbA1c adds a 90-day glycemic average. The American Diabetes Association's 2024 Standards of Care define prediabetes at HbA1c 5.7 to 6.4% and recommend screening in any adult with BMI ≥ 25 kg/m² (or ≥ 23 kg/m² in Asian Americans) [4]. DEXA-derived body fat percentage often reclassifies patients who appear "normal weight" by BMI but carry excess adiposity, a phenotype sometimes called "normal-weight obesity" or "thin-fat" body composition.

The lipid panel closes the cardiometabolic loop. An elevated triglyceride-to-HDL ratio (above 3.5 in non-Hispanic White populations, above 2.5 in others) correlates with insulin resistance almost as well as the gold-standard hyperinsulinemic clamp [5]. Pairing that ratio with DEXA android/gynoid fat distribution gives you a practical visceral adiposity risk estimate without ordering a CT scan.

Hormones: Testosterone, Estradiol, Thyroid

Lean mass on DEXA is a downstream readout of hormonal status. If the number is low or declining, you need hormone data to determine whether pharmacologic intervention (TRT, estradiol replacement, thyroid optimization) is appropriate.

For men, order total testosterone, free testosterone (equilibrium dialysis or calculated from SHBG), and SHBG. The Endocrine Society's 2018 guideline on testosterone therapy recommends measuring morning total testosterone on two separate days before diagnosing hypogonadism, with a threshold of <300 ng/dL for most assays [6]. A man whose DEXA shows progressive lean mass loss and whose total testosterone sits at 280 ng/dL has a clear treatment target. A man with the same DEXA trend but testosterone at 550 ng/dL needs a different workup (consider thyroid, cortisol, protein intake, or training stimulus).

For women, estradiol and FSH are the primary add-ons, especially in the perimenopausal window (ages 40 to 55). The 2022 North American Menopause Society position statement notes that estradiol decline drives a 1 to 2% annual loss in lean mass during the menopause transition [7]. If DEXA confirms that trajectory and serum estradiol is <30 pg/mL with FSH above 25 mIU/mL, hormone replacement therapy becomes a conversation with clear objective data behind it.

For everyone, order TSH and free T4. Subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) is present in roughly 5 to 8% of adults and can quietly reduce resting energy expenditure by 10 to 15%, promoting fat accumulation without obvious symptoms [8]. A rising DEXA fat mass percentage with stable caloric intake should trigger a thyroid check before assuming noncompliance.

Inflammatory Markers: hsCRP and the Adipose-Inflammation Axis

High-sensitivity C-reactive protein (hsCRP) bridges the gap between body composition and cardiometabolic risk. The JUPITER trial (N=17,802) demonstrated that hsCRP ≥ 2.0 mg/L independently predicts cardiovascular events even in patients with LDL cholesterol <130 mg/dL [9]. Adipose tissue is not inert storage. It produces interleukin-6, which drives hepatic CRP synthesis. More fat mass generally means higher hsCRP, but the relationship is not linear.

Some patients carry significant fat mass with hsCRP below 1.0 mg/L (metabolically healthy obesity), while others show elevated hsCRP at modest adiposity levels. Pairing DEXA fat mass data with hsCRP creates a two-axis risk profile that neither test provides alone. The American Heart Association and CDC jointly recommend classifying hsCRP as low risk (<1.0 mg/L), moderate risk (1.0 to 3.0 mg/L), or high risk (>3.0 mg/L) for cardiovascular event prediction [10].

If hsCRP is persistently above 3.0 mg/L, consider adding fasting glucose, uric acid, and a hepatic panel to screen for metabolic syndrome and non-alcoholic fatty liver disease (now called MASLD). A 2021 analysis in Hepatology found that DEXA trunk fat mass predicted liver fat content with an AUROC of 0.81, performing nearly as well as the fatty liver index [11].

Micronutrient and Nutritional Markers

A DEXA scan that shows declining lean mass often prompts protein supplementation advice. That advice is incomplete without checking the micronutrients that regulate muscle protein synthesis, bone mineralization, and energy metabolism.

25-hydroxyvitamin D is the most common deficiency relevant to body composition. The Endocrine Society's 2024 updated guideline recommends serum levels of 30 to 50 ng/mL for musculoskeletal health, with supplementation at 1,500 to 2,000 IU daily for adults found to be below 30 ng/mL [12]. Vitamin D receptors are expressed in skeletal muscle, and a meta-analysis of 29 RCTs (N=4,907) published in Medicine & Science in Sports & Exercise showed that correcting deficiency (from <20 ng/mL to >30 ng/mL) improved lower-extremity strength by a standardized mean difference of 0.34 (95% CI 0.13 to 0.54) [13].

Ferritin screens for iron deficiency before anemia develops. Women on caloric restriction (common among patients seeking DEXA monitoring) are at high risk. Ferritin below 30 ng/mL indicates depleted iron stores even if hemoglobin is normal.

RBC magnesium is a better tissue marker than serum magnesium. The AACE's 2023 clinical review on magnesium notes that "serum magnesium reflects less than 1% of total body stores and misses intracellular depletion in a majority of deficient patients" [14]. Low magnesium impairs insulin signaling and muscle contractility, both of which affect DEXA outcomes over time.

Bone-Specific Add-Ons When Lean Mass Is Low

DEXA body composition scans report bone mineral content and density alongside soft tissue data. If the scan reveals low lean mass, bone risk rises because muscle and bone are mechanically and hormonally coupled. The mechanostat model proposed by Harold Frost holds that bone adapts its mass to the peak mechanical loads placed on it, and the primary source of those loads is skeletal muscle contraction [15].

When lean mass is below the 25th percentile for age and sex, add intact PTH (parathyroid hormone) and 25-OH vitamin D to the panel. Elevated PTH (above 65 pg/mL) with low vitamin D suggests secondary hyperparathyroidism, a condition that accelerates cortical bone loss. The USPSTF recommends bone density screening for all women aged 65 and older and for younger postmenopausal women at elevated fracture risk [16]. Low lean mass on DEXA, paired with elevated PTH, may shift that screening recommendation earlier.

For patients on GLP-1 receptor agonists, bone surveillance gains added urgency. A post-hoc analysis of the STEP-1 trial (N=1,961) found that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo [17]. Roughly 40% of the weight lost on GLP-1s is lean mass rather than fat mass, per a 2023 analysis in Obesity using DEXA sub-studies [18]. Ordering DEXA with paired bone and muscle markers every 12 to 16 weeks during GLP-1 therapy helps clinicians detect when lean mass loss becomes disproportionate and warrants resistance training prescription or protein target adjustment.

How GLP-1 Therapy Changes the Paired-Testing Strategy

Patients on semaglutide or tirzepatide present a specific monitoring challenge. Body weight drops, but the composition of that weight loss matters. AACE's 2023 obesity algorithm explicitly recommends body composition assessment during anti-obesity medication therapy: "Serial DEXA or equivalent body composition assessment should be considered in patients on pharmacotherapy to ensure lean mass preservation" [19].

Dr. Caroline Apovian, co-director of the Center for Weight Management at Brigham and Women's Hospital, stated in a 2023 JAMA commentary that "we cannot accept a therapy that produces 15% weight loss if 6% of that is muscle. The whole point of precision obesity medicine is to lose fat and keep muscle" [20]. That statement sets the clinical standard: DEXA alone does not confirm muscle preservation. You need testosterone (in men), estradiol (in women), vitamin D, protein intake data, and inflammatory markers running in parallel to interpret the DEXA trend.

The SURMOUNT-1 trial of tirzepatide (N=2,539) reported 22.5% body weight reduction at 72 weeks on the 15 mg dose [21]. DEXA sub-analysis showed lean mass represented 33% of the total weight lost, somewhat better than historical GLP-1 data. These are population averages, though. Individual patients need individual tracking, which is exactly what paired DEXA-plus-labs provides.

Practical Test-Ordering Checklist by Clinical Scenario

Scenario 1: Baseline body composition assessment (no medications) Order DEXA, CMP, fasting insulin, HbA1c, lipid panel, hsCRP, TSH with free T4, 25-OH vitamin D, total testosterone/SHBG (men) or estradiol/FSH (women).

Scenario 2: GLP-1 therapy monitoring (every 12 to 16 weeks) Order DEXA, fasting insulin, HbA1c, lipid panel, CMP (watch eGFR and albumin for nutritional status), hsCRP, 25-OH vitamin D. Add PTH if previous DEXA showed low lean mass or declining bone density.

Scenario 3: TRT or HRT monitoring (every 6 months) Order DEXA, total/free testosterone or estradiol (matching therapy), hematocrit (TRT patients, due to erythrocytosis risk), PSA (men over 40 on TRT per Endocrine Society recommendation), lipid panel, HbA1c.

Scenario 4: Suspected sarcopenic obesity (high fat mass, low lean mass) Order DEXA, fasting insulin, HbA1c, hsCRP, TSH/free T4, total testosterone or estradiol, 25-OH vitamin D, PTH, ferritin, RBC magnesium, albumin, prealbumin. The prealbumin half-life is 2 to 3 days, making it a better acute marker of protein status than albumin (half-life 20 days) [22].

How to Read Your Results as a Unified Dataset

DEXA numbers exist in context. A body fat percentage of 28% in a 45-year-old man has different clinical implications depending on whether his fasting insulin is 5 µIU/mL or 25 µIU/mL, whether his testosterone is 700 ng/dL or 250 ng/dL, and whether his hsCRP is 0.5 mg/L or 4.2 mg/L.

The American College of Sports Medicine defines "normal" DEXA body fat ranges as 10 to 22% for men and 20 to 32% for women, though these are population-derived and do not account for age, ethnicity, or hormonal status [23]. A DEXA fat mass index (FMI, calculated as fat mass in kg divided by height in meters squared) above 9 kg/m² in men or 13 kg/m² in women correlates with metabolic syndrome components more reliably than BMI alone, as shown in a 2020 Journal of Clinical Endocrinology & Metabolism analysis (N=5,440) [24].

Interpreting lean mass requires the appendicular lean mass index (ALMI), calculated as total appendicular lean mass divided by height squared. The Foundation for the National Institutes of Health Sarcopenia Project set cut-points at <7.26 kg/m² for men and <5.45 kg/m² for women to define low lean mass [25]. Falling below those thresholds, combined with low testosterone, low vitamin D, or elevated PTH, identifies patients who benefit most from anabolic intervention (resistance training, protein optimization, hormone replacement).

When to Retest

Retest cadence depends on intervention. Patients starting GLP-1 therapy should repeat DEXA plus metabolic labs at 12 to 16 weeks, then every 16 to 24 weeks during active weight loss. Once weight stabilizes, every 6 to 12 months suffices for maintenance monitoring. Patients on TRT or HRT should repeat DEXA at 6 months, then annually, because hormonal changes in lean mass plateau by 12 to 18 months per the Testosterone Trials (TTrials, N=790) [26].

For patients not on pharmacotherapy who are using DEXA purely for fitness or aging surveillance, annual testing with paired labs is reasonable. More frequent testing risks capturing normal biological variation (hydration shifts, glycogen loading) rather than true compositional change. The minimum detectable change for DEXA whole-body lean mass is approximately 1.0 kg, so do not over-interpret shifts smaller than that between scans [2].